

Official Protocol Title (common title) (source, reference #)

1. A Multi-National Phase III Study of Satraplatin Plus Prednisone or Placebo Plus Prednisone in Patients With Hormone Refractory Prostate Cancer Previously Treated With One Cytotoxic Chemotherapy Regimen (Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen) (www.clinicaltrials.gov NCT00069745)
2. A Phase III, Randomized Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer (Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer) (www.clinicaltrials.gov NCT00036556)
3. A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer (Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer) (www.clinicaltrials.gov NCT00286091)
4. A Phase III Randomized, Open-Label Study of CG1940 and CG8711 Versus Docetaxel and Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer Who Are Chemotherapy-Naïve (GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer) (www.clinicaltrials.gov NCT00089856)
5. A Phase III Trial Comparing Docetaxel Every Third Week to Biweekly Docetaxel Monotherapy in Metastatic Hormone Refractory Prostate Cancer Patients - PROSTY Trial (Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic Prostate Cancer) (www.clinicaltrials.gov NCT00255606)
6. Phase III Study of Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients With Advanced Hormone Refractory Prostate Cancer (Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy) (www.clinicaltrials.gov NCT00134056)
7. A PHASE III STUDY OF THREE DIFFERENT DOSES OF SURAMIN (NSC #34936) ADMINISTERED WITH A FIXED DOSING SCHEDULE IN PATIENTS WITH ADVANCED PROSTATE CANCER (Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer) (www.clinicaltrials.gov NCT00002723)
8. A PHASE III TWO-ARM RANDOMIZED STUDY COMPARING ANTIANDROGEN WITHDRAWAL ALONE VERSUS ANTIANDROGEN WITHDRAWAL COMBINED WITH KETOCONAZOLE AND HYDROCORTISON IN PATIENTS WITH ADVANCED PROSTATE CANCER (Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer) (www.clinicaltrials.gov NCT00002760)

9. A Phase III Extension Study to Evaluate the Safety of 10 mg Atrasentan in Men With Hormone-Refractory Prostate Cancer (Atrasentan in Treating Patients With Prostate Cancer) (www.clinicaltrials.gov NCT00046943)
10. A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of the Matrix Metalloprotease Inhibitor AG3340 in Combination With Mitoxantrone and Prednisone With Provision for Subsequent Change in Therapy in Patients Having Hormone-Refractory Prostate Cancer (Chemotherapy in Treating Patients Who Have Metastatic Prostate Cancer) (www.clinicaltrials.gov NCT00003343)
11. Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC) Previously Treated With Unlimited Cytotoxic Chemotherapy Regimen (SPERA) (Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC) (SPERA)) (www.clinicaltrials.gov NCT00450970)
12. A Phase III Randomized, Open-Label Study of Docetaxel in Combination With CG1940 and CG8711 Versus Docetaxel and Prednisone in Taxane-Naïve Patients With Metastatic Hormone-Refractory Prostate Cancer With Pain (Docetaxel in Combination With GVAX[®] Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients) (www.clinicaltrials.gov NCT00133224)
13. A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa[®]) in the Treatment of Bone Metastases in Men With Hormone-Refractory Prostate Cancer (Double-Blind Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Metastases in Men With Hormone-Refractory Prostate Cancer) (www.clinicaltrials.gov NCT00321620)
14. Docetaxel and Estramustine Versus Mitoxantrone and Prednisone for Advanced, Hormone Refractory Prostate Cancer (Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy) (www.clinicaltrials.gov NCT00004001)
15. A PROSPECTIVE MULTICENTER RANDOMIZED STUDY COMPARING STRONTIUM-89 CHLORIDE AND PALLIATIVE LOCAL FIELD RADIOTHERAPY IN PATIENTS WITH HORMONAL ESCAPED ADVANCED PROSTATIC CANCER (Strontium Compared With Radiation Therapy in Treating Patients With Hormone-Refractory Prostate Cancer With Painful Bone Metastases) (www.clinicaltrials.gov NCT00002503)
16. A Randomized, Open-Label Phase II/III Study of SU101 Plus Mitoxantrone/Prednisone Compared to Mitoxantrone/Prednisone Alone in Patients With Hormone-Refractory Prostate Cancer (Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer) (www.clinicaltrials.gov NCT00004071)

17. Randomized Placebo-Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone Alone in Patients With Hormone Refractory Metastatic Prostate Cancer and Pain (Combination Chemotherapy in Treating Pain in Patients With Hormone Refractory Metastatic Prostate Cancer) (www.clinicaltrials.gov NCT00003232)
18. A Randomized, Double Blind, Placebo Controlled Phase 3 Trial of Immunotherapy With Autologous Antigen Presenting Cells Loading With PA2024 (Provenge(R), APC8015) in Men With Metastatic Androgen Independent Prostatic Adenocarcinoma (Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy) (www.clinicaltrials.gov NCT00065442)
19. Randomized, Open Label Multi-Center Study of XRP6258 in Combination With Prednisone Compared to Mitoxantrone in Combination With Prednisone For The Treatment of Hormone Refractory Metastatic Prostate Cancer Previously Treated With A Taxotere®-Containing Regimen (XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer (TROPIC)) (www.clinicaltrials.gov NCT00417079)
20. A Phase 3, Randomized, Open-Label Study Evaluating DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (ASCENT-2) (DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2]))(www.clinicaltrials.gov NCT00273338)
21. A Multicenter, Randomized, Double Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated With Docetaxel/ Prednisone for Metastatic Androgen-Independent Prostate Cancer (Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer (VENICE)) (www.clinicaltrials.gov NCT00519285)
22. RANDOMIZED PHASE III STUDY OF JM-216 ORAL PLATINUM PLUS PREDNISONE OR PREDNISONE ALONE IN PATIENTS WITH HORMONE REFRACTORY PROSTATE CANCER (protocol 30972) (www.eortc.be)
23. A Randomized Double-Blind Placebo Controlled Phase III Trial Evaluating Zoledronate Plus Standard Therapy Versus Placebo Plus Standard Therapy in Patients With Recurrent Carcinoma of the Prostate Who Are Asymptomatic With Castrate Levels of Testosterone and Have Rising PSA Levels Without Radiologically-Evident Metastatic Disease (Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms) (www.clinicaltrials.gov NCT00005073)
24. A Prospective Randomized Phase III, Trial Comparing Consolidation Therapy With or Without Strontium-89 Following Induction Chemotherapy in Androgen-Independent Prostate Cancer (Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer) (www.clinicaltrials.gov NCT00024167)